Patents by Inventor Adrian Pickar Oliver

Adrian Pickar Oliver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genome engineering with Type I CRISPR systems in eukaryotic cells
    Patent number: 11970710
    Abstract: Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system related compositions and methods of using said Type I CRISPR/Cas system related compositions for altering gene expression and genome engineering. The invention relates to compositions comprising Type I CRISPR-Cas polypeptides and CRISPR array nucleic acids designed for genome modification in eukaryotic cells and for targeted killing of eukaryotic cells.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: April 30, 2024
    Assignees: Duke University, North Carolina State University
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver, Chase Beisel
  • Genome engineering with Type I CRISPR systems in eukaryotic cells
    Patent number: 11905526
    Abstract: Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system related compositions and methods of using said Type I CRISPR/Cas system related compositions for altering gene expression and genome engineering. The invention relates to compositions comprising Type I CRISPR-Cas polypeptides and CRISPR array nucleic acids designed for genome modification in eukaryotic cells and for targeted killing of eukaryotic cells.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: February 20, 2024
    Assignees: Duke University, North Carolina State University
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver, Chase Beisel
  • CRISPR/CAS9 THERAPIES FOR CORRECTING DUCHENNE MUSCULAR DYSTROPHY BY TARGETED GENOMIC INTEGRATION
    Publication number: 20230257723
    Abstract: Disclosed herein arm CRISPR/Cas-based genome editing compositions and methods for treating Duchenne Muscular Dystrophy by restoring dystrophin function. The CRISPR/Cas-based genome editing systems may include a guide RNA (gRNA) targeting a fragment of a mutant dystrophin gene, a Cas protein or a fusion protein comprising the Cas protein, and a donor sequence comprising a fragment of a wild-type dystrophin gene.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 17, 2023
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver
  • Genome engineering with type I CRISPR systems in eukaryotic cells
    Patent number: 11421251
    Abstract: Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system related compositions and methods of using said Type I CRISPR/Cas system related compositions for altering gene expression and genome engineering. The invention relates to compositions comprising Type I CRISPR-Cas polypeptides and CRISPR array nucleic acids designed for genome modification in eukaryotic cells and for targeted killing of eukaryotic cells.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: August 23, 2022
    Assignees: Duke University, North Carolina State University
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver, Chase Beisel
  • CRISPR/CAS-BASED GENOME EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION
    Publication number: 20220195406
    Abstract: Disclosed herein are CRISPR/Cas-based genome editing compositions and methods for treating Duchenne Muscular Dystrophy by restoring dystrophin function.
    Type: Application
    Filed: April 14, 2020
    Publication date: June 23, 2022
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver
  • GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES
    Publication number: 20200347105
    Abstract: Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) programmable systems and methods of using said Type I CRISPR/Cas programmable systems for activating gene expression, repressing gene expression, and gene editing. The disclosure relates to compositions that include Type I CRISPR-Cas fusion proteins designed for transcriptional activation, transcriptional repression, and/or gene editing of target genes in eukaryotic cells. The disclosure relates to Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) transcriptional activation system related compositions and methods of using said Type I CRISPR/Cas transcriptional activation system related compositions for activating gene expression. The disclosure relates to compositions that include a Type I CRISPR-Cas fusion protein designed for transcriptional activation of target genes in eukaryotic cells.
    Type: Application
    Filed: January 19, 2019
    Publication date: November 5, 2020
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver, Rodolphe Barrangou
  • GENOME ENGINEERING WITH TYPE I CRISPR SYSTEMS IN EUKARYOTIC CELLS
    Publication number: 20200318139
    Abstract: Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system related compositions and methods of using said Type I CRISPR/Cas system related compositions for altering gene expression and genome engineering. The invention relates to compositions comprising Type I CRISPR-Cas polypeptides and CRISPR array nucleic acids designed for genome modification in eukaryotic cells and for targeted killing of eukaryotic cells.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 8, 2020
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver, Chase Beisel